{"analyses":[{"ciLowerLimit":"0.50","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.70","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.0001","pValueComment":"Two-sided significance level = 0.05","paramType":"Hazard Ratio (HR)","paramValue":"0.59","statisticalComment":"Reference arm is 70.2 Gy arm","statisticalMethod":"Gray's test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"36.6","upperLimit":"43.7","value":"40.2"},{"groupId":"OG001","lowerLimit":"22.1","upperLimit":"28.4","value":"25.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"751"},{"groupId":"OG001","value":"748"}],"units":"Participants"}],"description":"Failure is defined as having 3 consecutive elevations of post-treatment PSA or starting hormones after one or more elevations in post-treatment PSA but before three consecutive elevations were documented. The failure day date was the midpoint between last non-rising PSA and first PSA rise. Failure rates are estimated by the cumulative incidence method. Patients last known to be alive are censored at date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"70.2 Gy 3D-CRT/IMRT: Radiation will be delivered via 3D conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT) in 1.8 Gy minimum dose fractions to a total of 70.2 Gy in 39 fractions. All fields treated once daily, five fractions per week. No more than 2% of the planning target volume and none of the clinical target volume may receive less than 70.2 Gy.","id":"OG000","title":"70.2 Gy"},{"description":"79.2 Gy 3D-CRT/IMRT: Radiation will be delivered via 3D conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT) in 1.8 Gy minimum dose fractions to a total of 79.2 Gy in 44 fractions. All fields treated once daily, five fractions per week. No more than 2% of the planning target volume and none of the clinical target volume may receive less than 79.2 Gy.","id":"OG001","title":"79.2 Gy"}],"paramType":"NUMBER","populationDescription":"All eligible patients who did not withdraw consent","reportingStatus":"POSTED","timeFrame":"From randomization to date of failure (3 consecutive rises) or death or last follow-up. Analysis occurred after patients have been potentially followed for 5 years.","title":"Prostate-specific Antigen (PSA) Failure by American Society for Therapeutic Radiology and Oncology (ASTRO) Definition","type":"SECONDARY","unitOfMeasure":"percentage of participants"}